Results 91 to 100 of about 1,763 (188)
Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors
Oligoprogression (OPD) of non-small-cell lung cancer (NSCLC) occurs in approximately half of patients under targeted compounds (TKI) and facilitates use of regional therapies that can prolong survival.
Gaissmaier, Lena +31 more
core +1 more source
BackgroundStereotactic body radiotherapy (SBRT) has emerged as a promising therapeutic approach for vertebral metastases, achieving high local control and safety.
Arkadiusz Moskwa +6 more
doaj +1 more source
Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer—Real World Outcomes After Two Years of Therapy (COPILOT) [PDF]
BACKGROUND: Seminal trials with first-line pembrolizumab for metastatic non-small cell lung cancer (NSCLC) mandated a maximum two-years treatment. We describe real-world outcomes of a multi-site Australian cohort of patients who completed two-years of ...
Warburton, L +11 more
core +2 more sources
Inflammatory myofibroblastic tumors of the uterus harboring a TNS1-ALK fusion are rare, and their response to the anaplastic lymphoma kinase (ALK) inhibitor alectinib, including the management of oligoprogression with stereotactic body radiotherapy, is ...
Hakan Özçelik +4 more
doaj +1 more source
Objective Poly (ADP-ribose) polymerase inhibitors (PARPi) have become a new standard of care for the maintenance treatment of advanced epithelial ovarian cancer.
Rigo, Michele +14 more
core +1 more source
International audienceBackgroundStereotactic irradiation (SBRT) is a standard of care for inoperable stage I lung cancer and brain oligometastases from lung cancer but is controversial for extracranial oligometastases. We assessed outcomes of lung cancer
Stefan, Dinu +27 more
core +1 more source
Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic Melanoma [PDF]
Nora, Sobrevilla-Moreno +5 more
openaire +2 more sources
e587 Background: SABR is increasingly used for the treatment of men with oligometastatic prostate cancer, including patients (pts) presenting with oligoprogression.
Vanessa S. Arciero +6 more
core +1 more source
Background: Stereotactic body radiotherapy (SBRT) targeted at metastatic sites of disease progression is emerging as a potential therapeutic approach for managing oligoprogressive prostate cancer. However, a definitive benefit has yet to be demonstrated.
Emanuele Chioccola +11 more
doaj +1 more source
Data on the efficacy of computer tomography guided brachytherapy (CT-BRT) for limited liver metastases is lacking; to assess CT-BRT’s role in inducedoligoprogression in colorectal cancer (CRC), we performed a retrospective cohort study on CRC patients ...
Paweł Cisek +8 more
doaj +1 more source

